Tharimmune, Inc. | WebDisclosure

Basculer en Français

8205	Companies
109399	Keywords
51579	Articles
60261	Press releases

Home
Companies
Tharimmune, Inc.

PRESS RELEASE

published on 02/20/2024 at 14:01, 8 months 13 days ago

Tharimmune Announces Positive Results in Phase 1 Clinical Trial of TH104, its Lead Clinical Therapeutic Candidate
Tharimmune, Inc. announces successful Phase 1 trial completion for TH104, a promising treatment for chronic pruritus in primary biliary cholangitis. The study shows positive safety and tolerability profile aligned with previous findings

Tharimmune Inc. TH104 Phase 1 Trial Chronic Pruritus Primary Biliary Cholangitis
BRIEF

published on 02/20/2024 at 14:01, 8 months 13 days ago

Tharimmune announces positive Phase 1 results for TH104 and funding until 2025

Biotechnology Phase 1 Clinical Trial Funding TH104 Primary Biliary Cholangitis
BRIEF

published on 02/20/2024 at 14:01, 8 months 13 days ago

Tharimmune annonce les résultats positifs de la Phase 1 pour TH104 et le financement jusqu'en 2025

Biotechnologie Financement TH104 Essai Clinique De Phase 1 Cholangite Biliaire Primitive
PRESS RELEASE

published on 02/05/2024 at 14:30, 8 months 28 days ago

Tharimmune Announces Dosing of First Patient in Phase 1 Clinical Trial of TH104, its Lead Candidate for Pruritus in Primary Biliary Cholangitis
Tharimmune, Inc. completes first patient dosing in Phase 1 clinical trial for TH104, an oral thin film targeting liver-related and pruritogenic inflammatory conditions. Topline data expected in 2Q24 with full readout shortly after. Company fully funded into 2025 for Phase 1 and 2 readouts

Phase 1 Clinical Trial Tharimmune Inc. TH104 Liver-related Conditions Pruritogenic Inflammatory Conditions
PRESS RELEASE

published on 01/29/2024 at 14:00, 9 months 6 days ago

Tharimmune Announces Initiation of Phase 1 Clinical Trial of TH104 and Provides Business Update
Tharimmune, Inc. initiates Phase 1 trial for TH104, a buccal film with nalmefene for liver-related pruritogenic inflammatory conditions. Phase 2 planning for PBC, near-clinical pipeline and R&D day planned. Company fully funded into 2025

Tharimmune Inc. TH104 Phase 1 Trial Buccal Film Chronic Pruritus
PRESS RELEASE

published on 12/11/2023 at 14:01, 10 months 24 days ago

Tharimmune Announces Positive Topline Data with TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Chronic Liver Disease Patients
PRESS RELEASE

published on 11/27/2023 at 14:00, 11 months 7 days ago

Tharimmune Reports Positive Phase 1 Data on TH104, its Lead Therapeutic Candidate, for Chronic Pruritis in Primary Biliary Cholangitis (PBC)

Accesswire

Published on 11/04/2024 at 21:45, 10 minutes ago

Hank Payments Responds to Press Release Issued By Melrose Ventures
Published on 11/04/2024 at 21:30, 25 minutes ago

Forward Water Technologies Corp. Announces Shares for Interest Debt Settlement
Published on 11/04/2024 at 20:45, 1 hour 10 minutes ago

Koilink Technologies Inc. Appoints Transfer Online Inc. as New Transfer Agent, Enhancing Shareholder Services Amid Progress Toward Public Listing
Published on 11/04/2024 at 19:00, 2 hours 55 minutes ago

Arctic IT Government Solutions Selected as an Information Technology Support Services Contractor for the U.S. Department of the Interior, Bureau of Indian Affairs
Published on 11/04/2024 at 18:15, 3 hours 40 minutes ago

Al Salam Bank Launches ASB Capital: A New Asset Management Firm in the DIFC with AUMs of USD 4.5 Billion

View all ACCESSWIRE

EQS Group

Published on 11/04/2024 at 21:15, 39 minutes ago

EQS-Adhoc: LEG Immobilien SE: Acquisition of Brack Capital Properties N.V. through the conclusion of a share purchase agreement and a tender commitment in the event of a public offer
Published on 11/04/2024 at 19:00, 2 hours 54 minutes ago

EQS-Adhoc: Salzgitter Aktiengesellschaft: Potential voluntary public takeover bid to the shareholders of Salzgitter AG
Published on 11/04/2024 at 19:00, 2 hours 54 minutes ago

PATRIMOINE ET COMMERCE: Déclaration des transactions sur actions propres (Hors contrat de liquidité) réalisées du 28 OCTOBRE 2024 au 01 NOVEMBRE 2024
Published on 11/04/2024 at 19:00, 2 hours 54 minutes ago

PATRIMOINE ET COMMERCE: INFORMATIONS RELATIVES AU NOMBRE TOTAL DE DROITS DE VOTE ET AU NOMBRE D’ACTIONS COMPOSANT LE CAPITAL SOCIAL AU TITRE DE L’ARTICLE 223-16 DU REGLEMENT GENERAL DE L'AMF
Published on 11/04/2024 at 18:47, 3 hours 7 minutes ago

Fuller, Smith & Turner PLC: Transaction in own shares

Les Echos

Published on 11/04/2024 at 18:13, 3 hours 41 minutes ago

Thales : lancement de l’opération 2024 d’actionnariat salarié
Published on 11/04/2024 at 18:13, 3 hours 41 minutes ago

Thales: Launch of the 2024 Employee Share Ownership Plan
Published on 11/04/2024 at 18:11, 3 hours 43 minutes ago

Monthly disclosure of the total number of shares and voting rights - 31/10/2024
Published on 11/04/2024 at 18:11, 3 hours 43 minutes ago

Déclaration mensuelle des actions et droits de vote – 31/10/2024
Published on 11/04/2024 at 17:45, 4 hours 10 minutes ago

Disclosure of trading in own shares from October 29th, 2024, to November 1st, 2024. Detailed information per transaction.

View all LES ECHOS COMFI WIRE